Cognitive status correlates with CXCL10/IP-10 levels in Parkinson's disease

Parkinson's Disease

Volumn 2014, Issue , 2014, Pages

  Rocha, Natália Pessoa ^a   Scalzo, Paula Luciana ^a   Barbosa, Izabela Guimarães ^a   Souza, Mariana Soares ^b   Morato, Isabela Boechat ^a   Vieira, Érica Leandro Marciano ^a   Christo, Paulo Pereira ^b   Teixeira, Antônio Lúcio ^a   Reis, Helton José ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Santa Casa Hospital de Belo Horizonte   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EOTAXIN; EOTAXIN 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1;

AGED; ARTICLE; BECK DEPRESSION INVENTORY; BODY MASS; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; FEMALE; HUMAN; MALE; MENTAL PERFORMANCE; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PILOT STUDY; PROTEIN BLOOD LEVEL; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 84908318178     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2014/903796     Document Type: Article

References (37)

1. Samii A., Nutt J. G., Ransom B. R., Parkinson's disease. The Lancet 2004 363 9423 1783 1793 10.1016/S0140-6736(04)16305-8 2-s2.0-2542596183
2. Bekris L. M., Mata I. F., Zabetian C. P., The genetics of Parkinson disease. Journal of Geriatric Psychiatry and Neurology 2010 23 4 228 242 10.1177/0891988710383572 2-s2.0-78649284891
3. Parkinson J., An essay on the shaking palsy. 1817. The Journal of Neuropsychiatry and Clinical Neurosciences 2002 14 2 223 236 10.1176/appi.neuropsych.14.2.223 2-s2.0-19044361911
4. McGeer P. L., Itagaki S., Boyes B. E., McGeer E. G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988 38 8 1285 1291 10.1212/WNL.38.8.1285 2-s2.0-0023789193
5. Collins L. M., Toulouse A., Connor T. J., Nolan Y. M., Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology 2012 62 7 2154 2168 10.1016/j.neuropharm.2012.01.028 2-s2.0-84871898081
6. Lindqvist D., Kaufman E., Brundin L., Hall S., Surova Y., Hansson O., Non-motor symptoms in patients with Parkinson's disease-correlations with inflammatory cytokines in serum. PLoS ONE 2012 7 10 e47387 10.1371/journal.pone.0047387 2-s2.0-84867629199
7. Katsarou Z., Bostantjopoulou S., Hatzizisi O., Giza E., Soler-Cardona A., Kyriazis G., Immune factors or depression? Fatigue correlates in Parkinson's disease. Revista de Neurologia 2007 45 12 725 728 2-s2.0-37549056264
8. Menza M., Dobkin R. D., Marin H., Mark M. H., Gara M., Bienfait K., Dicke A., Kusnekov A., The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics 2010 51 6 474 479 10.1176/appi.psy.51.6.474 2-s2.0-78649686234
9. Chen-Plotkin A. S., Hu W. T., Siderowf A., Weintraub D., Goldmann Gross R., Hurtig H. I., Xie S. X., Arnold S. E., Grossman M., Clark C. M., Shaw L. M., McCluskey L., Elman L., Van Deerlin V. M., Lee V. M.-Y., Soares H., Trojanowski J. Q., Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Annals of Neurology 2011 69 4 655 663 10.1002/ana.22271 2-s2.0-79955389388
10. Réaux-Le Goazigo A., van Steenwinckel J., Rostène W., Mélik Parsadaniantz S., Current status of chemokines in the adult CNS. Progress in Neurobiology 2013 104 67 92 10.1016/j.pneurobio.2013.02.001 2-s2.0-84876799802
11. Guyon A., Skrzydelski D., De Giry I., Rovère C., Conductier G., Trocello J. M., Daugé V., Kitabgi P., Rostène W., Nahon J. L., Mélik Parsadaniantz S., Long term exposure to the chemokine CCL2 activates the nigrostriatal dopamine system: a novel mechanism for the control of dopamine release. Neuroscience 2009 162 4 1072 1080 10.1016/j.neuroscience.2009.05.048 2-s2.0-68049123116
12. Shimoji M., Pagan F., Healton E. B., Mocchetti I., CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson's disease. Neurotoxicity Research 2009 16 3 318 328 10.1007/s12640-009-9076-3 2-s2.0-70349909667
13. Ross O. A., O'Neill C., Rea I. M., Lynch T., Gosal D., Wallace A., Curran M. D., Middleton D., Gibson J. M., Functional promoter region polymorphism of the proinflammatory chemokine IL-8 gene associates with Parkinson's disease in the Irish. Human Immunology 2004 65 4 340 346 10.1016/j.humimm.2004.01.015 2-s2.0-2142849942
14. Rentzos M., Nikolaou C., Andreadou E., Paraskevas G. P., Rombos A., Zoga M., Tsoutsou A., Boufidou F., Kapaki E., Vassilopoulos D., Circulating interleukin-15 and RANTES chemokine in Parkinson's disease. Acta Neurologica Scandinavica 2007 116 6 374 379 10.1111/j.1600-0404.2007.00894.x 2-s2.0-35748932913
15. Reale M., Iarlori C., Thomas A., Gambi D., Perfetti B., Di Nicola M., Onofrj M., Peripheral cytokines profile in Parkinson's disease. Brain, Behavior, and Immunity 2009 23 1 55 63 10.1016/j.bbi.2008.07.003 2-s2.0-56849086964
16. Grassi-Oliveira R., Brieztke E., Teixeira A., Pezzi J. C., Zanini M., Lopes R. P., Bauer M. E., Peripheral chemokine levels in women with recurrent major depression with suicidal ideation. Revista Brasileira de Psiquiatria 2012 34 1 71 75 10.1590/S1516-44462012000100013 2-s2.0-84858065556
17. Barbosa I. G., Rocha N. P., Bauer M. E., Chemokines in bipolar disorder: trait or state? European Archives of Psychiatry and Clinical Neuroscience 2013 263 2 159 165 10.1007/s00406-012-0327-6 2-s2.0-84879504095
18. Asevedo E., Gadelha A., Noto C., Mansur R. B., Zugman A., Belangero S. I. N., Berberian A. A., Scarpato B. S., Leclerc E., Teixeira A. L., Gama C. S., Bressan R. A., Brietzke E., Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia. Journal of Psychiatric Research 2013 47 10 1376 1382 10.1016/j.jpsychires.2013.05.032 2-s2.0-84881548759
19. Fontenelle L. F., Barbosa I. G., Luna J. V., de Sousa L. P., Abreu M. N. S., Teixeira A. L., A cytokine study of adult patients with obsessive-compulsive disorder. Comprehensive Psychiatry 2012 53 6 797 804 10.1016/j.comppsych.2011.12.007 2-s2.0-84864125789
20. Soares H. D., Potter W. Z., Pickering E., Kuhn M., Immermann F. W., Shera D. M., Ferm M., Dean R. A., Simon A. J., Swenson F., Siuciak J. A., Kaplow J., Thambisetty M., Zagouras P., Koroshetz W. J., Wan H. I., Trojanowski J. Q., Shaw L. M., Plasma biomarkers associated with the apolipoprotein E genotype and alzheimer disease. Archives of Neurology 2012 69 10 1310 1317 10.1001/archneurol.2012.1070 2-s2.0-84867340530
21. Aarsland D., Påhlhagen S., Ballard C. G., Ehrt U., Svenningsson P., Depression in Parkinson disease-epidemiology, mechanisms and management. Nature Reviews Neurology 2012 8 1 35 47 10.1038/nrneurol.2011.189 2-s2.0-84555189257
22. Bugalho P., Vale J., Brief cognitive assessment in the early stages of parkinson disease. Cognitive and Behavioral Neurology 2011 24 4 169 173 10.1097/WNN.0b013e3182350a1f 2-s2.0-83655163736
23. Kummer A., Teixeira A. L., Neuropsychiatry of Parkinson's disease. Arquivos de Neuro-Psiquiatria 2009 67 3 930 939 10.1590/S0004-282X2009000500033 2-s2.0-71949114587
24. Stuart M. J., Baune B. T., Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: a systematic review of biomarker studies. Neuroscience & Biobehavioral Reviews 2014 42 93 115 10.1016/j.neubiorev.2014.02.001
25. Hughes A. J., Daniel S. E., Kilford L., Lees A. J., Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery & Psychiatry 1992 55 3 181 184 10.1136/jnnp.55.3.181 2-s2.0-0026514953
26. Fahn S., Elton R., Fahn S., Marsden C. D., Caine D. B., Goldstein M., Unified Parkinson's disease rating scale. Recent Developments in Parkinson's Disease 1987 2 153-163, 293 304
27. Hoehn M. M., Yahr M. D., Parkinsonism: onset, progression and mortality. Neurology 1967 17 5 427 442 10.1212/WNL.17.5.427 2-s2.0-0014082977
28. Folstein M. F., Folstein S. E., Mchugh P. R., "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975 12 189 198
29. Dubois B., Slachevsky A., Litvan I., Pillon B., The FAB: a frontal assessment battery at bedside. Neurology 2000 55 11 1621 1626 10.1212/WNL.55.11.1621 2-s2.0-0034642168
30. Beck A. T., Ward C. H., Mendelson M., Mock J., Erbaugh J., An inventory for measuring depression. Archives of General Psychiatry 1961 4 561 571 10.1001/archpsyc.1961.01710120031004 2-s2.0-70350654728
31. Scalzo P., de Miranda A. S., Guerra Amaral D. C., de Carvalho Vilela M., Cardoso F., Teixeira A. L., Serum levels of chemokines in parkinson's disease. Neuroimmunomodulation 2011 18 4 240 244 10.1159/000323779 2-s2.0-79952819709
32. Lindqvist D., Hall S., Surova Y., Nielsen H. M., Janelidze S., Brundin L., Hansson O., Cerebrospinal fluid inflammatory markers in Parkinson's disease-associations with depression, fatigue, and cognitive impairment. Brain, Behavior, and Immunity 2013 33 183 189 10.1016/j.bbi.2013.07.007 2-s2.0-84883771075
33. Shi M., Bradner J., Hancock A. M., Chung K. A., Quinn J. F., Peskind E. R., Galasko D., Jankovic J., Zabetian C. P., Kim H. M., Leverenz J. B., Montine T. J., Ginghina C., Kang U. J., Cain K. C., Wang Y., Aasly J., Goldstein D., Zhang J., Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Annals of Neurology 2011 69 3 570 580 10.1002/ana.22311 2-s2.0-79953283868
34. Morganti J. M., Nash K. R., Grimmig B. A., The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson's disease. The Journal of Neuroscience 2012 32 42 14592 14601 10.1523/JNEUROSCI.0539-12.2012 2-s2.0-84867617885
35. Tousi N. S., Buck D. J., Curtis J. T., Davis R. L., α-Synuclein potentiates interleukin-1 β -induced CXCL10 expression in human A172 astrocytoma cells. Neuroscience Letters 2012 507 2 133 136 10.1016/j.neulet.2011.12.001 2-s2.0-84855328900
36. Galimberti D., Schoonenboom N., Scheltens P., Fenoglio C., Bouwman F., Venturelli E., Guidi I., Blankenstein M. A., Bresolin N., Scarpini E., Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Archives of Neurology 2006 63 4 538 543 10.1001/archneur.63.4.538 2-s2.0-33645731581
37. Galimberti D., Venturelli E., Fenoglio C., Lovati C., Guidi I., Scalabrini D., Mariani C., Bresolin N., Scarpini E., IP-10 serum levels are not increased in mild cognitive impairment and Alzheimer's disease. European Journal of Neurology 2007 14 4 e3 e4 10.1111/j.1468-1331.2006.01637.x 2-s2.0-33947603002